Nipocalimab — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

8 Recruiting

3 Completed trials

1 Sponsors

21 Countries

Phase III

Phase II/III

Phase II

Phase III: 7 Phase II/III: 2 Phase II: 3

Indications tested

Myasthenia gravis 3 Neonatal alloimmune thrombocytopenia 2 Chronic inflammatory demyelinating polyradiculoneuropathy 1 Sjogren´s syndrome 1 Rheumatoid arthritis 1 Systemic lupus erythematosus 1

Sponsors using this IMP

Janssen - Cilag International 12

All trials

12 total

Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC Pending

2025-521130-28-00 Phase III 4 countries Janssen Cilag International
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Phase III 15 countries Janssen Cilag International
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F… Recruiting

2023-509434-19-00 Phase III 4 countries Janssen Cilag International
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neona… Recruiting

2023-504307-88-00 Phase III 10 countries Janssen - Cilag International
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Phase III 15 countries Janssen Cilag International
A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting

2022-502629-16-00 Phase III 11 countries Janssen - Cilag International
Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting

2023-508425-28-00 Phase II 8 countries Janssen Cilag International
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Child… Recruiting

2022-502539-21-00 Phase II/III 2 countries Janssen - Cilag International
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting

2023-504152-97-00 Phase III 9 countries Janssen - Cilag International
Efficacy and Safety Study of Nipocalimab for Adults with Active Inflammatory Myopathies Ended

2023-505314-20-00 Phase II 7 countries Janssen - Cilag International
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu… Ended

2023-505321-14-00 Phase II/III 9 countries Janssen - Cilag International
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended

2023-504045-31-00 Phase II 3 countries Janssen - Cilag International

Showing 1–12 of 12 trials

← All drugs A–Z